Novel Vaccine Combinations: towards and HIV vaccine
Novel vaccine combinations
• Results and implications of proof-of-concept study testing MVA, Ad26, and Ad35 vector-based vaccines
• Evaluating the protective efficacy of several prime-boost vaccine combinations
• Insight into “immune correlates”
The need for an HIV vaccine is undeniable. Dr Hanneke Schuitemaker, Senior Vice President, Viral Vaccine Discovery and Early Development, Professor in Virology, Crucell joined us at the World Vaccine Congress Lyon in 2012 to discuss novel vaccine combinations that could lead to the development of an HIV vaccine.
He begins by outlining the goals for an ideal HIV Vaccine:
• Protect against acquisition of HIV
– most likely through eliciting broad humoral immune responses
• Reduce (peak) viral load in breakthrough infections
– most likely through broad and potent cellular immunity
– To reduce time to clinical disease or antiviral therapy
– Potentially to lower transmission and help control the epidemic
The building blocks for an HIV vaccine that induces broad humoral and cellular immunity according to Dr Schuitemaker are:
• Mosaic antigens
• Trimeric GP 140
• Viral vectors
• Adjuvant
Why not download the full presentation to find out more about Novel vaccine combinations including:
• Results and implications of proof-of-concept study testing MVA, Ad26, and Ad35 vector-based vaccines
• Evaluating the protective efficacy of several prime-boost vaccine combinations
• Insight into “immune correlates”
Download the full presentation here >